WallStSmart

Alvotech (ALVO)vsTeva Pharma Industries Ltd ADR (TEVA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Teva Pharma Industries Ltd ADR generates 3401% more annual revenue ($17.32B vs $494.61M). TEVA leads profitability with a 4.1% profit margin vs -36.3%. TEVA earns a higher WallStSmart Score of 49/100 (D+).

ALVO

Avoid

16

out of 100

Grade: F

Growth: 4.7Profit: 3.0Value: 6.7Quality: 5.5
Piotroski: 2/9Altman Z: -1.02

TEVA

Hold

49

out of 100

Grade: D+

Growth: 5.3Profit: 5.0Value: 5.0Quality: 3.5
Piotroski: 6/9Altman Z: 0.28
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ALVOUndervalued (+72.3%)

Margin of Safety

+72.3%

Fair Value

$17.49

Current Price

$5.29

$12.20 discount

UndervaluedFair: $17.49Overvalued

Intrinsic value data unavailable for TEVA.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ALVO1 strengths · Avg: 10.0/10
Debt/EquityHealth
-7.5810/10

Conservative balance sheet, low leverage

TEVA2 strengths · Avg: 9.0/10
EPS GrowthGrowth
72.2%10/10

Earnings expanding 72.2% YoY

PEG RatioValuation
0.678/10

Growing faster than its price suggests

Areas to Watch

ALVO4 concerns · Avg: 2.8/10
Market CapQuality
$1.86B3/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Revenue GrowthGrowth
-38.9%2/10

Revenue declined 38.9%

TEVA4 concerns · Avg: 2.5/10
Profit MarginProfitability
4.1%3/10

4.1% margin — thin

Operating MarginProfitability
4.0%3/10

Operating margin of 4.0%

P/E RatioValuation
61.3x2/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
-0.8%2/10

Revenue declined 0.8%

Comparative Analysis Report

WallStSmart Research

Bull Case : ALVO

The strongest argument for ALVO centers on Debt/Equity.

Bull Case : TEVA

The strongest argument for TEVA centers on EPS Growth, PEG Ratio. PEG of 0.67 suggests the stock is reasonably priced for its growth.

Bear Case : ALVO

The primary concerns for ALVO are Market Cap, Return on Equity, Piotroski F-Score.

Bear Case : TEVA

The primary concerns for TEVA are Profit Margin, Operating Margin, P/E Ratio. A P/E of 61.3x leaves little room for execution misses. Debt-to-equity of 2.18 is elevated, increasing financial risk.

Key Dynamics to Monitor

ALVO profiles as a turnaround stock while TEVA is a value play — different risk/reward profiles.

TEVA carries more volatility with a beta of 0.87 — expect wider price swings.

TEVA is growing revenue faster at -0.8% — sustainability is the question.

TEVA generates stronger free cash flow (307M), providing more financial flexibility.

Bottom Line

TEVA scores higher overall (49/100 vs 16/100). ALVO offers better value entry with a 72.3% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Alvotech

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Alvotech Holdings SA, develops and manufactures biosimilars for global markets. The company is headquartered in Iceland.

Visit Website →

Teva Pharma Industries Ltd ADR

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.

Want to dig deeper into these stocks?